BioSpace

Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial

Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.

作者 BioSpace

1 分钟阅读
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察